Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Can-Fite BioPharma Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Can-Fite BioPharma kazanç ve gelirinin sırasıyla yıllık 38.2% ve 67.5% oranında artması tahmin edilirken, EPS'nin yıllık 171.4% oranında büyümesi bekleniyor.

Anahtar bilgiler

38.2%

Kazanç büyüme oranı

171.4%

EPS büyüme oranı

Biotechs kazanç büyümesi	45.2%
Gelir büyüme oranı	67.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	24 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19

Kazanç ve Gelir Büyüme Tahminleri

TASE:CANF - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	0	-8	20	-9	2
12/31/2025	11	1	21	21	3
12/31/2024	1	-8	-9	-9	3
6/30/2024	1	-7	-7	-7	N/A
3/31/2024	1	-7	N/A	N/A	N/A
12/31/2023	1	-8	-8	-8	N/A
9/30/2023	1	-9	N/A	N/A	N/A
6/30/2023	1	-10	-10	-10	N/A
3/31/2023	1	-10	N/A	N/A	N/A
12/31/2022	1	-10	-11	-11	N/A
9/30/2022	1	-14	N/A	N/A	N/A
6/30/2022	1	-15	-12	-12	N/A
3/31/2022	1	-16	N/A	N/A	N/A
12/31/2021	1	-15	-10	-10	N/A
9/30/2021	1	-12	N/A	N/A	N/A
6/30/2021	1	-11	-7	-7	N/A
3/31/2021	1	-12	N/A	N/A	N/A
12/31/2020	1	-15	-12	-12	N/A
9/30/2020	1	-13	N/A	N/A	N/A
6/30/2020	2	-17	-14	-14	N/A
3/31/2020	2	-13	N/A	N/A	N/A
12/31/2019	2	-13	-11	-11	N/A
9/30/2019	2	-11	N/A	N/A	N/A
6/30/2019	4	-8	-8	-8	N/A
3/31/2019	3	-7	N/A	N/A	N/A
12/31/2018	4	-7	-4	-4	N/A
9/30/2018	4	-5	N/A	N/A	N/A
6/30/2018	2	-6	-5	-5	N/A
3/31/2018	1	-5	N/A	N/A	N/A
12/31/2017	1	-6	N/A	-9	N/A
9/30/2017	1	-6	N/A	N/A	N/A
6/30/2017	0	-9	N/A	-9	N/A
3/31/2017	0	-7	N/A	N/A	N/A
12/31/2016	0	-8	N/A	-9	N/A
9/30/2016	0	-5	N/A	N/A	N/A
6/30/2016	0	-6	N/A	-8	N/A
3/31/2016	0	-6	N/A	N/A	N/A
12/31/2015	0	-6	N/A	-5	N/A
9/30/2015	0	-7	N/A	N/A	N/A
6/30/2015	0	-5	N/A	-5	N/A
3/31/2015	N/A	-5	N/A	N/A	N/A
12/31/2014	N/A	-6	N/A	-7	N/A
9/30/2014	N/A	-7	N/A	N/A	N/A
6/30/2014	N/A	-8	N/A	-9	N/A
3/31/2014	N/A	-8	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CANF önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: CANF önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: CANF önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: CANF şirketinin gelirinin (yıllık 67.5% ) IL pazarından (yıllık 2.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CANF şirketinin gelirinin (yıllık 67.5% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CANF 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Can-Fite BioPharma Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2023

No longer forecast to breakeven

Recent updates

Can-Fite BioPharma Ltd. Receives Approval from Israeli Ministry of Health to Conduct Phase IIa Clinical Trial with Orally-Administered Namodenoson in Treatment of Pancreatic Carcinoma

New major risk - Shareholder dilution

Insufficient new directors

First half 2024 earnings released: US$0.002 loss per share (vs US$0.004 loss in 1H 2023)

Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix

Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study

Can-Fite BioPharma Ltd., Annual General Meeting, Jun 26, 2024

New minor risk - Share price stability

Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022)

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Financial data availability

First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022)

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022)

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Insufficient new directors

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021)

Forecast to breakeven in 2023

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021)

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Insufficient new directors

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate

Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022

We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans

Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Can-Fite Biopharma Ltd. Commences Clinical Study for the Treatment of Canine Osteoarthritis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?